keyword
https://read.qxmd.com/read/38655277/case-report-when-cystic-fibrosis-elexacaftor-tezacaftor-ivacaftor-therapy-and-alpha1-antitrypsin-deficiency-get-together
#1
Rachel Kinuani, Jessica Ezri, Yann Kernen, Isabelle Rochat, Sylvain Blanchon
In the last 10 years, the care of patients with cystic fibrosis (CF) has been revolutionized with the introduction of cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs, with a major impact on symptoms and life expectancy, especially considering the newest and highly effective elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) therapy. Conversely, adverse effects are relatively frequent, with some being life-threatening, such as severe hepatitis. Clinical trials on children starting CFTR modulators have reported transaminase elevations >3× upper limit of the norm in 10%-20% of patients, whereas real-life studies have reported discontinuation rates three times higher than those observed in phase 3 trials...
2024: Frontiers in Pediatrics
https://read.qxmd.com/read/38653109/pharmacological-inhibition-of-the-src-homology-phosphatase-2-confers-partial-protection-in-a-mouse-model-of-alcohol-associated-liver-disease
#2
JOURNAL ARTICLE
Ming-Fo Hsu, Shinichiro Koike, Chang-Shan Chen, Sonia M Najjar, Tzu-Ching Meng, Fawaz G Haj
Alcohol-associated liver disease (ALD) is a leading factor of liver-related death worldwide. ALD has various manifestations that include steatosis, hepatitis, and cirrhosis and is currently without approved pharmacotherapies. The Src homology phosphatase 2 (Shp2) is a drug target in some cancers due to its positive regulation of Ras-mitogen-activated protein kinase signaling and cell proliferation. Shp2 pharmacological inhibition yields beneficial outcomes in animal disease models, but its impact on ALD remains unexplored...
April 22, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38652863/visualization-of-endogenous-hypochlorite-in-drug-induced-liver-injury-mice-via-a-bioluminescent-probe-combined-with-firefly-luciferase-mrna-loaded-lipid-nanoparticles
#3
JOURNAL ARTICLE
Jieyu Yang, Zhaoming Chen, Yuexia Yang, Bingbing Zheng, Yu Zhu, Fapu Wu, Hu Xiong
Drug-induced liver injury (DILI) is a common liver disease with a high rate of morbidity, and its pathogenesis is closely associated with the overproduction of highly reactive hypochlorite (ClO- ) in the liver. However, bioluminescence imaging of endogenous hypochlorite in nontransgenic natural mice remains challenging. Herein, to address this issue, we report a strategy for imaging ClO- in living cells and DILI mice by harnessing a bioluminescent probe formylhydrazine luciferin ( ClO-Luc ) combined with firefly luciferase (fLuc) mRNA-loaded lipid nanoparticles (LNPs)...
April 23, 2024: Analytical Chemistry
https://read.qxmd.com/read/38651230/buprenorphine-affects-the-initiation-and-severity-of-interleukin-induced-acute-pancreatitis-in-mice
#4
JOURNAL ARTICLE
Sarah Jahangir, Biswajit Khatua, Nabil Smichi, Prasad Rajalingamgari, Anoop Narayana Pillai, Megan J Summers, Bryce McFayden, Sergiy Kostenko, Naomi M Gades, Vijay P Singh
Acute pancreatitis (AP) is a common disease with no targeted therapy and has varied outcomes ranging from spontaneous resolution to being lethal. While typically painful, AP can also be painless. Various agents, including opioids are used for pain control in AP; the risks, and benefits of which are often debated. Since experimental AP in mice is used to study the efficacy of potential therapies, we studied the effect of a commonly used opioid buprenorphine on the initiation and progression of AP. For this we administered extended-release buprenorphine subcutaneously prior to inducing the previously established severe AP model that uses Interleukins 12 and 18 (IL12,18) in genetically obese (ob/ob) mice and compared this to mice with AP but without the drug...
April 23, 2024: American Journal of Physiology. Gastrointestinal and Liver Physiology
https://read.qxmd.com/read/38650929/ferroptosis-in-liver-cancer-a-key-role-of-post-translational-modifications
#5
REVIEW
Ying Xu, Zhiyao Xing, Ruaa Abdalla Ibrahim Suliman, Zichuan Liu, Fengyuan Tang
Ferroptosis is an emerging form of regulated cell death in an oxidative stress- and iron-dependent manner, primarily induced by the over-production of reactive oxygen species (ROS). Manipulation of ferroptosis has been considered a promising therapeutic approach to inhibit liver tumor growth. Nevertheless, the development of resistance to ferroptosis in liver cancer poses a significant challenge in cancer treatment. Post-translational modifications (PTMs) are crucial enzymatic catalytic reactions that covalently regulate protein conformation, stability and cellular activities...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38649362/hepatic-sirt6-activation-abrogates-acute-liver-failure
#6
JOURNAL ARTICLE
Jinque Luo, Huan Liu, Yanni Xu, Nanhui Yu, Rebbeca A Steiner, Xiaoqian Wu, Shuyi Si, Zheng Gen Jin
Acute liver failure (ALF) is a deadly illness due to insufficient detoxification in liver induced by drugs, toxins, and other etiologies, and the effective treatment for ALF is very limited. Among the drug-induced ALF, acetaminophen (APAP) overdose is the most common cause. However, the molecular mechanisms underlying APAP hepatoxicity remain incompletely understood. Sirtuin 6 (Sirt6) is a stress responsive protein deacetylase and plays an important role in regulation of DNA repair, genomic stability, oxidative stress, and inflammation...
April 22, 2024: Cell Death & Disease
https://read.qxmd.com/read/38644704/vigilance-needed-in-treating-a-child-with-disseminated-tb-a-case-report
#7
Hemasri Velmurugan, Krishnapriya Neelambaran, Meenalotchini Prakash Gurunthalingam, Dushyant Chouhan, Pugazhenthan Thangaraju, Bikram Keshari Kar, Nitin Rewaram Gaikwad
BACKGROUND: Tuberculosis is still one of the biggest causes of infection-related death around the world. Disseminated tuberculosis is a potentially fatal disease caused by the haematogenous spread of Mycobacterium tuberculosis. First-line anti-tuberculosis drugs in-clude isoniazid, rifampicin, pyrazinamide, and ethambutol. The first three drugs are known to cause hepatotoxicity. CASE PRESENTATION: We have, herein, reported a case of Drug-induced Liver Injury (DILI) due to anti-tuberculosis therapy in a one-year-old male child with disseminated tuberculosis...
April 19, 2024: Infectious Disorders Drug Targets
https://read.qxmd.com/read/38644297/hellp-syndrome-at-20-gestational-weeks-managed-using-the-mississippi-protocol-a-case-report
#8
JOURNAL ARTICLE
Naohisa Masuko, Kenji Tanimura, Masayuki Tanaka, Akiko Uchida, Ryosuke Takahashi, Hitomi Imafuku, Masashi Deguchi, Yoshito Terai
Hemolysis, elevated liver enzyme levels, and low platelet count (HELLP) syndrome is one of the most severe complications of hypertensive disorders of pregnancy. HELLP syndrome occurring before 22 gestational weeks (GWs) is extremely rare, and patients prevalently exhibit underlying maternal diseases or fetal abnormalities. Here, we report the case of a pregnant woman who had HELLP syndrome at 20 GWs without any obvious underlying maternal diseases or fetal abnormalities. A 38-year-old pregnant woman was referred to Kobe University Hospital from another hospital at 19 + 5/7 GWs for hypertension, proteinuria, generalized edema, and fetal growth restriction...
April 1, 2024: Kobe Journal of Medical Sciences
https://read.qxmd.com/read/38643381/cenicriviroc-a-ccr2-ccr5-antagonist-promotes-the-generation-of-type-1-regulatory-t-cells
#9
JOURNAL ARTICLE
Upasna Madan, Bhawna Verma, Amit Awasthi
Cenicriviroc, a dual CCR2/CCR5 antagonist, initially developed as an anti-HIV drug, has shown promising results in nonalcoholic steatohepatitis phase 2 clinical trials. It inhibits the infiltration and activation of CCR2+ /CCR5+ monocytes and macrophages to the site of liver injury, preventing liver fibrosis. However, the role of Cenicriviroc in the modulation of helper T cell differentiation and functions remains to be explored. In inflamed colons of Crohn's disease patients, CCR2+ and CCR5+ CD4+ T cells are enriched...
April 21, 2024: European Journal of Immunology
https://read.qxmd.com/read/38643122/interpretable-machine-learning-in-predicting-drug-induced-liver-injury-among-tuberculosis-patients-model-development-and-validation-study
#10
JOURNAL ARTICLE
Yue Xiao, Yanfei Chen, Ruijian Huang, Feng Jiang, Jifang Zhou, Tianchi Yang
BACKGROUND: The objective of this research was to create and validate an interpretable prediction model for drug-induced liver injury (DILI) during tuberculosis (TB) treatment. METHODS: A dataset of TB patients from Ningbo City was used to develop models employing the eXtreme Gradient Boosting (XGBoost), random forest (RF), and the least absolute shrinkage and selection operator (LASSO) logistic algorithms. The model's performance was evaluated through various metrics, including the area under the receiver operating characteristic curve (AUROC) and the area under the precision recall curve (AUPR) alongside the decision curve...
April 20, 2024: BMC Medical Research Methodology
https://read.qxmd.com/read/38642890/mir-141-200c-contributes-to-ethanol-mediated-hepatic-glycogen-metabolism
#11
JOURNAL ARTICLE
Melanie Tran, Shaynian Gilling, Jianguo Wu, Li Wang, Dong-Ju Shin
OBJECTIVE: Hepatic glucose metabolism is profoundly perturbed by excessive alcohol intake. miR-141/200c expression is significantly induced by chronic ethanol feeding. This study aimed at identifying the role of miR-141/200c in glucose homeostasis during chronic ethanol exposure. METHODS: WT and miR-141/200c KO mice were fed a control or an ethanol diet for 30 days, followed by a single binge of maltose dextrin or ethanol, respectively. Untargeted metabolomics analysis of hepatic primary metabolites was performed along with analyses for liver histology, gene expression, intracellular signaling pathways, and physiological relevance...
April 18, 2024: Molecular Metabolism
https://read.qxmd.com/read/38642504/theabrownin-from-qingzhuan-tea-prevents-high-fat-diet-induced-masld-via-regulating-intestinal-microbiota
#12
JOURNAL ARTICLE
Yong Chen, Chen Xie, Yining Lei, Dan Ye, Le Wang, Fang Xiong, Hui Wu, Qiang He, Hongfu Zhou, Ling Li, Jun Xing, Cai Wang, Min Zheng
The aim of this study was to investigate whether the therapeutic effect of theabrownin extracted from Qingzhuan tea (QTB) on metabolic dysfunction-associated steatosis liver disease (MASLD) is related to the regulation of intestinal microbiota and its metabolite short-chain fatty acids (SCFAs). Mice were divided into four groups and received normal diet (ND), high-fat diet (HFD) and HFD+QTB (180, 360 mg/kg) for 8 weeks. The results showed that QTB significantly reduced the body weight of HFD mice, ameliorated liver lipid and dyslipidemia, and increased the level of intestinal SCFAs in HFD mice...
April 19, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38642343/recam-j-2023-validation-and-development-of-the-japanese-version-of-recam-for-the-diagnosis-of-drug-induced-liver-injury
#13
JOURNAL ARTICLE
Atsushi Tanaka, Keiji Tsuji, Yasuyuki Komiyama, Kota Tsuruya, Keisuke Kakisaka, Akemi Tsutsui, Keiko Ichimoto, Masayuki Ueno, Yuki Okazaki, Hiroteru Kamimura, Atsushi Takai, Noriyo Yamashiki, Takanori Ito, Masaaki Watanabe, Masanori Abe, Ken-Ichi Harada, Tatehiro Kagawa
AIM: The diagnosis of drug-induced liver injury (DILI) is challenging. We modified the revised electronic version of the Roussel Uclaf Causality Assessment Method (RUCAM) for the diagnosis of DILI (RECAM), the scoring system developed in US and Spanish cohorts in 2022, and developed RECAM-J 2023 to align with the clinical practice in Japan. In the current study, we introduce RECAM-J 2023 and verify its performance in the context of Japanese patients with DILI. METHODS: After translation of RECAM into Japanese, modifications were made to develop RECAM-J 2023 without any alteration to the scores...
April 20, 2024: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://read.qxmd.com/read/38642292/composite-plot-for-visualizing-aminotransferase-and-bilirubin-changes-in-clinical-trials-of-subjects-with-abnormal-baseline-values
#14
JOURNAL ARTICLE
Bereket Tesfaldet, Tejas Patel, Minjun Chen, Frank Pucino, Lilliam Rosario, Paul Hayashi, Eileen Navarro Almario
INTRODUCTION: On-treatment excursions of liver laboratory test values in clinical trials involving subjects with underlying liver disease are relevant for the efficacy and safety assessment of drug products and biologics. Existing visualization and analysis tools do not efficiently provide an integrated view of these excursions when baseline liver tests are abnormal. OBJECTIVE: The aim of this study was to develop a composite plot that enables visualization of on-treatment changes in liver test results both as multiples of the upper limit of normal defined by each laboratory's reference population (×ULN) and multiples of the subjects' baseline (×BLN) values...
April 20, 2024: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://read.qxmd.com/read/38640709/role-of-ghrelin-hormone-in-the-development-of-alcohol-associated-liver-disease
#15
JOURNAL ARTICLE
Sundararajan Mahalingam, Ramesh Bellamkonda, Kusum K Kharbanda, Madan Kumar Arumugam, Vikas Kumar, Carol A Casey, Lorenzo Leggio, Karuna Rasineni
Fatty liver is the earliest response of the liver to excessive alcohol consumption. Previously we identified that chronic alcohol administration increases levels of stomach-derived hormone, ghrelin, which by reducing circulating insulin levels, ultimately contributes to the development of alcohol-associated liver disease (ALD). In addition, ghrelin directly promotes fat accumulation in hepatocytes by enhancing de novo lipogenesis. Other than promoting ALD, ghrelin is known to increase alcohol craving and intake...
April 18, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38632021/the-effect-of-statins-on-the-risk-of-anti-tuberculosis-drug-induced-liver-injury-among-patients-with-active-tuberculosis-a-cohort-study
#16
JOURNAL ARTICLE
Chun-Kai Huang, Jei-Yie Huang, Chin-Hao Chang, Shang-Jie Tsai, Chin-Chung Shu, Hao-Chien Wang, Kuo-Liong Chien
BACKGROUND: Tuberculosis (TB) remains prevalent worldwide, and anti-TB drugs are associated with drug-induced liver injury (DILI). Statins have pleiotropic effects which may decrease inflammation and achieve immunomodulation. However, few studies have investigated the pleiotropic effects of statins on the risk of DILI. The purpose of this study was to investigate whether statins prevent anti-tuberculosis DILI among active TB patients on standard anti-TB drug therapy. METHODS: We conducted a hospital-based retrospective cohort study using claims data from the Integrated Medical Database of National Taiwan University Hospital (NTUH-iMD)...
April 8, 2024: Journal of Microbiology Immunology and Infection
https://read.qxmd.com/read/38631865/the-influence-of-emodin-succinyl-ethyl-ester-on-non-alcoholic-steatohepatitis-induced-by-a-diet-high-in-fructose-cholesterol-and-fat-in-mice
#17
JOURNAL ARTICLE
Yanxue Wang, Liang Li, Lingling Chen, Jinlei Xia, Tongli Wang, Lei Han, Liang Cao, Zhenzhong Wang, Wei Xiao, Shan Jiang
Nonalcoholic steatohepatitis (NASH) is a subtype of nonalcoholic fatty liver disease (NAFLD) characterized by hepatic steatosis and evidence of hepatocyte injury (ballooning) and inflammation, with or without liver fibrosis. In this study, after 12 weeks of induction, the mice were treated with emodin succinyl ethyl ester (ESEE) for four weeks at doses of 10/30/90 mg/kg/day. The blood analysis of experimental endpoints showed that ESEE exhibited significant therapeutic effects on the progression of disorders of glycolipid metabolism and the induced liver injury in the model animals...
April 18, 2024: Biological & Pharmaceutical Bulletin
https://read.qxmd.com/read/38631510/triclocarban-induces-lipid-droplet-accumulation-and-oxidative-stress-responses-by-inhibiting-mitochondrial-fatty-acid-oxidation-in-heparg-cells
#18
JOURNAL ARTICLE
Hitoshi Nakamura, Toshikatsu Matsui, Tadahiro Shinozawa
Mitochondrial fatty acid oxidation (mtFAO) plays an important role in hepatic energy metabolism. Severe mtFAO injury leads to nonalcoholic fatty liver disease (NAFLD) and liver failure. Several drugs have been withdrawn owing to safety issues, such as induction of fatty liver disease through mtFAO disruption. For instance, the antimicrobial triclocarban (TCC), an environmental contaminant that was removed from the market due to its unknown safety in humans, induces NAFLD in rats and promotes hepatic FAO in mice...
April 15, 2024: Toxicology Letters
https://read.qxmd.com/read/38630788/afriplex-grttm-extract-attenuates-hepatic-steatosis-in-an-in-vitro-model-of-nafld
#19
JOURNAL ARTICLE
Kwazi Gabuza, Thendo I Mabuda, Oelfah Patel, Noxolo Khuboni, Ruzayda van Aarde, Sylvia Riedel, Nonhlakanipho F Sangweni, Shantal Windvogel, Rabia Johnson, Christo J F Muller
BACKGROUND: Currently, it is acknowledged that vitamin E, insulin sensitizers and anti-diabetic drugs are used to manage non-alcoholic fatty liver disease (NAFLD), however, these therapeutic interventions harbour adverse side effects. Pioglitazone, an anti-diabetic drug, is currently the most effective therapy to manage NAFLD. The use of natural medicines is widely embraced due to the lack of evidence of their negative side effects. Rooibos has been previously shown to decrease inflammation and oxidative stress in experimental models of diabetes, however, this is yet to be explored in a setting of NAFLD...
2024: PloS One
https://read.qxmd.com/read/38630781/safety-pharmacokinetics-pharmacodynamics-and-antitumor-activity-from-a-phase-i-study-of-simlukafusp-alfa-fap-il2v-in-advanced-metastatic-solid-tumors
#20
JOURNAL ARTICLE
Neeltje Steeghs, Carlos Gomez-Roca, Kristoffer S Rohrberg, Morten Mau-Sørensen, Debbie Robbrecht, Josep Tabernero, Samreen Ahmed, Maria E Rodriguez-Ruiz, Caroline Ardeshir, Daniela Schmid, Nassim Sleiman, Carl Watson, Hanna Piper-Lepoutre, David Dejardin, Stefan Evers, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Ignacio Melero
PURPOSE: Simlukafusp alfa (FAP-IL2v), a tumor-targeted immunocytokine, comprising an interleukin-2 variant moiety with abolished CD25 binding fused to human immunoglobulin G1, is directed against fibroblast activation protein-α. This phase I, open-label, multicenter, dose-escalation and extension study (NCT02627274) evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of FAP-IL2v in patients with advanced/metastatic solid tumors. METHODS: Participants received FAP-IL2v intravenously once weekly...
April 17, 2024: Clinical Cancer Research
keyword
keyword
113156
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.